ATEC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $192 million, up 14% year-over-year, but below internal expectations.
Surgical Revenue: $178 million, up 17% year-over-year, but down 6% sequentially.
EBITDA: $21 million, representing 11% of revenue, with a 97% year-over-year increase.
Cash Flow: Used $11 million in cash, attributed to timing and intent; ended the quarter with approximately $140 million in cash.
Gross Margin: Improved to 71.6%, up over 120 basis points year-over-year.
Surgeon Adoption: Increased by 23%, with case volume growth of 21%.

2. Strategic Updates and Business Highlights

ATEC is focusing on building a durable growth model, emphasizing surgeon adoption and procedural efficiency.
The EOS Insight platform is evolving into a significant asset, providing access to prestigious institutions and driving case volume.
The company is investing in sales and marketing to bolster EOS performance, which saw revenue of $14 million, down from the previous year.
The installed base of EOS units grew by 7% year-over-year, with EOSedge installations up 39%.
ATEC is enhancing its capital structure with a new Term Loan A and revolving credit facility, expected to save $35 million in interest over its life.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Total revenue expected to be approximately $882 million, reflecting 15% growth year-over-year.
Surgical Revenue: Expected to remain at $805 million, unchanged from prior guidance, with a growth rate of 17%.
EOS Revenue: Revised down to approximately $77 million due to near-term execution issues.
Adjusted EBITDA: Expected to be approximately $134 million, maintaining a 15% margin.
Free Cash Flow: Projected to be at least $20 million for the full year, with Q2 expected to approximate zero.

4. Bad News, Challenges, or Points of Concern

EOS Sales Performance: Revenue from EOS was below expectations, attributed to lower system deliveries and execution challenges.
Revenue Per Procedure Decline: Revenue per case declined approximately 3% year-over-year, primarily due to a higher mix of lower-revenue cervical procedures and lower biologics attachment rates.
Sequential Revenue Decline: Surgical revenue saw a 6% decline sequentially, which is more pronounced than historical trends.
Execution Issues: Challenges in installation timing for EOS units have led to missed revenue targets, creating uncertainty in the short term.

5. Notable Q&A Insights

Long-Range Plan (LRP) Confidence: Management reaffirmed confidence in the $1 billion revenue target for 2027, despite current execution challenges.
Surgeon Adoption Trends: Continued strong surgeon adoption is seen as a leading indicator for future growth, with a focus on expanding both breadth and depth in the market.
Revenue Per Case Outlook: Guidance suggests flat revenue per procedure for the year, with potential headwinds from ongoing cervical procedure growth.
EOS Strategic Position: Management remains optimistic about EOS's role in the procedural ecosystem, emphasizing its unique data capabilities and potential for long-term growth despite current challenges.

Overall, while ATEC faced some execution challenges in Q1 2026, the company maintains a positive outlook driven by strong surgeon adoption and a commitment to strategic investments in its EOS platform and sales force.

ATEC — Alphatec Holdings, Inc.